Skip to main content
SpringerLink
Log in

Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?

  • Practice Point
  • Published:

From Nature Clinical Practice Cardiovascular Medicine

View current issue Sign up to alerts

An Erratum to this article was published on 01 September 2006

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Douketis JD et al. (2005) Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 29: 1153–1167

    Article  CAS  Google Scholar 

  2. Curioni CC and Lourenco PM (2005) Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 29: 1168–1174

    Article  CAS  Google Scholar 

  3. Padwal R et al. (2006) Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD004094

    Google Scholar 

  4. James WP et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356: 2119–2125

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Claire Braybrook, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Nutrition and Head Physician in the Department of Preventive Cardiology, University of Oslo, Oslo, Norway

    Serena Tonstad

Authors
  1. Serena Tonstad
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

S Tonstad has received honoraria from Sanofi-Aventis, the manufacturers of rimonabant for consulting and lectures, as well as Roche and Abbott, the manufacturers of orlistat and sibutramine, respectively.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonstad, S. Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?. Nat Rev Cardiol 3, 364–365 (2006). https://doi.org/10.1038/ncpcardio0598

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0598

  • Springer Nature Limited

This article is cited by

Search

Navigation